Cancer epigenetics: an introduction
- PMID: 25421652
- DOI: 10.1007/978-1-4939-1804-1_1
Cancer epigenetics: an introduction
Abstract
Epigenetic and genetic alterations contribute to cancer initiation and progression. Epigenetics refers to the study of heritable changes in gene expression without alterations in DNA sequences. Epigenetic changes are reversible and include key processes of DNA methylation, chromatin modifications, nucleosome positioning, and alterations in noncoding RNA profiles. Disruptions in epigenetic processes can lead to altered gene function and cellular neoplastic transformation. Epigenetic modifications precede genetic changes and usually occur at an early stage in neoplastic development. Recent technological advances offer a better understanding of the underlying epigenetic alterations during carcinogenesis and provide insight into the discovery of putative epigenetic biomarkers for detection, prognosis, risk assessment, and disease monitoring. In this chapter we provide information on various epigenetic mechanisms and their role in carcinogenesis, in particular, epigenetic modifications causing genetic changes and the potential clinical impact of epigenetic research in the future.
Similar articles
-
Epigenetic modifications in cancer.Clin Genet. 2012 Apr;81(4):303-11. doi: 10.1111/j.1399-0004.2011.01809.x. Epub 2011 Dec 8. Clin Genet. 2012. PMID: 22082348 Free PMC article. Review.
-
Cancer epigenetics.CA Cancer J Clin. 2010 Nov-Dec;60(6):376-92. doi: 10.3322/caac.20085. Epub 2010 Oct 19. CA Cancer J Clin. 2010. PMID: 20959400 Review.
-
Introduction: epigenetics and cancer.Adv Genet. 2010;70:1-23. doi: 10.1016/B978-0-12-380866-0.60001-0. Adv Genet. 2010. PMID: 20920743
-
Discovery and development of DNA methylation-based biomarkers for lung cancer.Epigenomics. 2014 Feb;6(1):59-72. doi: 10.2217/epi.13.81. Epigenomics. 2014. PMID: 24579947
-
Epigenetic biomarkers for human cancer: the time is now.Crit Rev Oncol Hematol. 2008 Oct;68(1):1-11. doi: 10.1016/j.critrevonc.2008.03.001. Epub 2008 Apr 21. Crit Rev Oncol Hematol. 2008. PMID: 18430583 Review.
Cited by
-
Advances in targeting cancer epigenetics using CRISPR-dCas9 technology: A comprehensive review and future prospects.Funct Integr Genomics. 2024 Sep 18;24(5):164. doi: 10.1007/s10142-024-01455-3. Funct Integr Genomics. 2024. PMID: 39292321 Review.
-
Nanomaterial-mediated autophagy: coexisting hazard and health benefits in biomedicine.Part Fibre Toxicol. 2020 Oct 16;17(1):53. doi: 10.1186/s12989-020-00372-0. Part Fibre Toxicol. 2020. PMID: 33066795 Free PMC article. Review.
-
Unveil Intrahepatic Cholangiocarcinoma Heterogeneity through the Lens of Omics and Multi-Omics Approaches.Cancers (Basel). 2024 Aug 20;16(16):2889. doi: 10.3390/cancers16162889. Cancers (Basel). 2024. PMID: 39199659 Free PMC article. Review.
-
Cancer epigenetics: from laboratory studies and clinical trials to precision medicine.Cell Death Discov. 2024 Jan 15;10(1):28. doi: 10.1038/s41420-024-01803-z. Cell Death Discov. 2024. PMID: 38225241 Free PMC article. Review.
-
Overexpression of KDM4D promotes acute myeloid leukemia cell development by activating MCL-1.Am J Transl Res. 2021 Apr 15;13(4):2308-2319. eCollection 2021. Am J Transl Res. 2021. PMID: 34017391 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
